Physician profile
Michael S Krathen
NPI 1932376050
$1,471.38
in general payments reported to CMS, 2019-2025
22 companies · $547 in 2025
The $547 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $156 · 2021: $58.12 · 2022: $143 · 2023: $194 · 2024: $189 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $831 · Education: $99.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $830.93 |
| Education | $99.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $354.58 | 2019-2025 | |
| Janssen Biotech, INC. | $206.90 | 2019-2025 | Tremfya |
| Ucb, INC. | $128.38 | 2023-2025 | Bimzelx |
| Lilly USA, LLC | $127.69 | 2019-2025 | Ebglyss, Taltz |
| Regeneron Healthcare Solutions, INC. | $127.42 | 2022-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $81.56 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $64.77 | 2025 | |
| Novartis Pharmaceuticals Corporation | $63.13 | 2019-2025 | |
| Galderma Laboratories, L.P. | $51.51 | 2024-2025 | Aklief, Nemluvio |
| Helsinn Therapeutics (U.S.), INC. | $31.53 | 2025 | Valchlor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.48 | 2023 | Cyltezo |
| Dermavant Sciences, INC. | $25.96 | 2024 | Vtama |
| Leo Pharma INC. | $24.98 | 2022 | |
| Incyte Corporation | $24.34 | 2024 | Opzelura |
| Botanix Sb INC | $22.78 | 2025 | Sofdra |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $20.85 | 2021 | |
| Genzyme Corporation | $20.74 | 2021 | |
| Arcutis Biotherapeutics, INC. | $18.61 | 2025 | Zoryve |
| Convatec INC. | $16.53 | 2021 | |
| Pfizer INC. | $14.64 | 2023 | |
| Nabriva Therapeutics, Plc | $14.00 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Krathen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.